| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
|
Pant, Shubham
|
|
2016
|
56 |
C |
p. 1-9
9 p.
|
artikel
|
| 2 |
Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX
|
Lledo, Gérard
|
|
2016
|
56 |
C |
p. 115-121
7 p.
|
artikel
|
| 3 |
Comment on “Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis”, published in Eur J Cancer 51 (2015), 1570–1579
|
Blanchard, Pierre
|
|
2016
|
56 |
C |
p. 183-185
3 p.
|
artikel
|
| 4 |
Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC – STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging
|
Messiou, C.
|
|
2016
|
56 |
C |
p. 37-44
8 p.
|
artikel
|
| 5 |
Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients
|
Lintermans, A.
|
|
2016
|
56 |
C |
p. 31-36
6 p.
|
artikel
|
| 6 |
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
|
Strasser-Weippl, Kathrin
|
|
2016
|
56 |
C |
p. 85-92
8 p.
|
artikel
|
| 7 |
Intraventricular methotrexate in addition to intravenous high dose methotrexate with folinic acid rescue: is it worth the bother?
|
Cohen, Emeritus Ian J.
|
|
2016
|
56 |
C |
p. 179-180
2 p.
|
artikel
|
| 8 |
Is cancer a good way to die? A population-based survey among middle-aged and older adults in the United Kingdom
|
Vrinten, Charlotte
|
|
2016
|
56 |
C |
p. 172-178
7 p.
|
artikel
|
| 9 |
Is there any benefit to adding adjuvant chemotherapy after concurrent chemoradiotherapy for nasopharyngeal carcinoma?
|
Yan, Marie
|
|
2016
|
56 |
C |
p. 186-187
2 p.
|
artikel
|
| 10 |
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes
|
Villaruz, Liza C.
|
|
2016
|
56 |
C |
p. 162-171
10 p.
|
artikel
|
| 11 |
Leptomeningeal metastasis: Clinical experience of 519 cases
|
Hyun, Jae-Won
|
|
2016
|
56 |
C |
p. 107-114
8 p.
|
artikel
|
| 12 |
Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment
|
Kloth, Jacqueline S.L.
|
|
2016
|
56 |
C |
p. 101-106
6 p.
|
artikel
|
| 13 |
Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)
|
Valentin, T.
|
|
2016
|
56 |
C |
p. 77-84
8 p.
|
artikel
|
| 14 |
Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation
|
Mercieca-Bebber, Rebecca L.
|
|
2016
|
56 |
C |
p. 144-161
18 p.
|
artikel
|
| 15 |
Polychlorinated biphenyls and their association with survival following breast cancer
|
Parada Jr., Humberto
|
|
2016
|
56 |
C |
p. 21-30
10 p.
|
artikel
|
| 16 |
Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold
|
Willemsen, Annelieke E.C.A.B.
|
|
2016
|
56 |
C |
p. 54-58
5 p.
|
artikel
|
| 17 |
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent
|
Haagensen, Emma J.
|
|
2016
|
56 |
C |
p. 69-76
8 p.
|
artikel
|
| 18 |
Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System
|
van Spronsen, Margot F.
|
|
2016
|
56 |
C |
p. 10-20
11 p.
|
artikel
|
| 19 |
Reply to letter that comments on ‘Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy’
|
Pompe, R.S.
|
|
2016
|
56 |
C |
p. 181-182
2 p.
|
artikel
|
| 20 |
Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy
|
Araki, Nobuhito
|
|
2016
|
56 |
C |
p. 122-130
9 p.
|
artikel
|
| 21 |
Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study
|
Markar, Sheraz R.
|
|
2016
|
56 |
C |
p. 59-68
10 p.
|
artikel
|
| 22 |
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial
|
Meisel, Alexander
|
|
2016
|
56 |
C |
p. 93-100
8 p.
|
artikel
|
| 23 |
Targeting the tumour microenvironment in ovarian cancer
|
Hansen, Jean M.
|
|
2016
|
56 |
C |
p. 131-143
13 p.
|
artikel
|
| 24 |
The burden of malignant melanoma – Lessons to be learned from Austria
|
Monshi, Babak
|
|
2016
|
56 |
C |
p. 45-53
9 p.
|
artikel
|
Tijdschrift beschrijving